• Sheffield et al. (2017). DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nature Medicine.
  • Kovar et al. (2016). The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget.
  • Zhang et al. (2015). Germline Mutations in Predisposition Genes in Pediatric Cancer. New England Journal of Medicine.
  • Gomez, and Davis (2015). Linking germline and somatic variation in Ewing sarcoma. Nature Genetics.
  • Grünewald et al. (2015). Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nature Genetics.
  • Tomazou et al. (2015). Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep.
  • Riggi et al. (2014). EWS-FLI1 Utilizes Divergent Chromatin Remodeling Mechanisms to Directly Activate or Repress Enhancer Elements in Ewing Sarcoma. Cancer Cell.
  • Tirode et al. (2014). Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations. Cancer Discovery.
  • Cornaz-Buros et al. (2014). Targeting Cancer Stem-like Cells as an Approach to Defeating Cellular Heterogeneity in Ewing Sarcoma. Cancer Research.
  • Sankar et al. (2014). Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clinical cancer research.
  • Zhou et al. (2014). EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology. Cancer.
  • Walters et al. (2014). JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene.
  • Stoll et al. (2013). Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Nucleic acids research.
  • Niedan et al. (2013). Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Oncogene.
  • Bilke et al. (2013). Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Research.
  • Sankar et al. (2013). EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma. Genes \& cancer.
  • Sankar et al. (2012). Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene.
  • David et al. (2012). Oncostatin M is a growth factor for Ewing sarcoma. The American journal of pathology.
  • De Vito et al. (2012). A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer cell.
  • Lawlor, and Thiele (2012). Epigenetic changes in pediatric solid tumors: promising new targets. Clinical cancer research.
  • Reynolds et al. (2012). NuRD suppresses pluripotency gene expression to promote transcriptional heterogeneity and lineage commitment. Cell stem cell.
  • Postel-Vinay et al. (2012). Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nature Genetics.
  • Patel et al. (2012). Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. Genome research.
  • Lessnick, and Ladanyi (2012). Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annual review of pathology.
  • Lin et al. (2011). Mesenchymal Stem Cells and the Origin of Ewing’s Sarcoma. Sarcoma.
  • von Levetzow et al. (2011). Modeling initiation of Ewing sarcoma in human neural crest cells. PloS one.
  • Desai, and Jambhekar (2010). Pathology of Ewing’s sarcoma/PNET: Current opinion and emerging concepts. Indian journal of orthopaedics.
  • Erkizan et al. (2010). Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing’s sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research.
  • Riggi et al. (2010). EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes and Development.
  • Le Deley et al. (2010). Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
  • Balamuth, and Womer (2010). Ewing’s sarcoma. The lancet oncology.
  • Suva et al. (2009). Identification of Cancer Stem Cells in Ewingtextquotesingles Sarcoma. Cancer Research.
  • Guillon et al. (2009). The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PloS one.
  • Kennedy, and DtextquotesingleAndrea (2006). DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes. Journal of Clinical Oncology.
  • Delattre et al. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature.
  • Rud et al. (1989). Extraosseous Ewing’s sarcoma. A study of 42 cases. Cancer.